NEWS
Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Mycosis Fungoides
Innate Pharma has announced positive results from its Phase 2 TELLOMAK study, evaluating lacutamab in patients with mycosis fungoides (MF), a type of cutaneous T cell lymphoma. The study, presented at ASCO 2024, included 107 heavily pretreated patients. Lacutamab demonstrated significant anti-tumor activity, with an objective response rate (ORR) of 22.4% per Olsen 2022 criteria and 16.8% per Olsen 2011 criteria. The median progression-free survival was 10.2 months, and the treatment was well-tolerated. These results support further development of lacutamab for MF patients, regardless of KIR3DL2 expression levels.
Innate Pharma has announced positive results from its Phase 2 TELLOMAK study, evaluating lacutamab in patients with mycosis fungoides (MF), a type of cutaneous T cell lymphoma. The study, presented at ASCO 2024, included 107 heavily pretreated patients. Lacutamab demonstrated significant anti-tumor activity, with an objective response rate (ORR) of 22.4% per Olsen 2022 criteria and 16.8% per Olsen 2011 criteria. The median progression-free survival was 10.2 months, and the treatment was well-tolerated. These results support further development of lacutamab for MF patients, regardless of KIR3DL2 expression levels.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1664Followers
92Following
13KVisitors
Follow